Biomedicine · eu
Restoring protein recycling in kidney cells: piclidenoson shows promise in Lowe syndrome models
Starting with a receptor on the cell membrane, researchers identified a pathway that bypasses the OCRL defect and adjusts lipid distribution within cells. Patient cells, kidney organoids and mice provided preclinical evidence, but whether this can improve kidney function in patients remains a question for human trials.
The kidneys filter blood every day and must also reclaim substances the body needs. In people with Lowe syndrome, this recycling mechanism can be disrupted by failures in intracellular transport, allowing proteins to be lost in urine. An Italian research team has now found that the drug candidate piclidenoson can improve this defect in several experimental models, offering a therapeutic pathway for this rare genetic disease that can be tested clinically.
Published in *Signal Transduction and Targeted Therapy*, the study was led by Antonella De Matteis’s team at the Telethon Institute of Genetics and Medicine (TIGEM). Lowe syndrome affects the eyes, nervous system and kidneys. The enzyme encoded by OCRL, the gene responsible for the disease, helps regulate phosphoinositide lipids on cell membranes. When the enzyme’s function is impaired, a lipid called PI(4,5)P₂, or PIP₂ for short, accumulates abnormally in endosomes, which sort cellular cargo.
Lipids in the wrong location can also disrupt receptor trafficking. The megalin receptor on the surface of kidney tubule cells normally captures proteins and returns to the cell surface after recycling is complete. In the disease state, however, it may become trapped in endosomes, reducing the cells’ ability to reabsorb proteins. This gave the researchers a clear screening objective: to find compounds that could restore normal cellular transport.
According to the Telethon Foundation, the team screened approximately 1,300 compounds and selected piclidenoson, also known as IB-MECA, after successive rounds of validation. It is an adenosine A3 receptor agonist that has previously been used in clinical studies of diseases including psoriasis. The current validation covered engineered cell lines, patient-derived kidney tubule cells, human kidney organoids and a humanized mouse model. Treated organoids regained their ability to reabsorb proteins, while protein levels in urine also fell after oral administration in mice.
The study indicates that activating the A3 receptor with the drug stimulates phospholipase C to break down PIP₂ on the cell membrane. Because at least some of the abnormal PIP₂ accumulation in endosomes is linked to its supply from the cell membrane, reducing the latter can ease the lipid imbalance in endosomes and improve receptor trafficking. This pathway does not depend on OCRL, suggesting that even while the disease-causing genetic defect remains, cells may be able to restore some function through another mechanism.
The next step is to determine whether these improvements can be reproduced in patients. According to the foundation, a study planned at Bambino Gesù Children’s Hospital in Rome, to be coordinated by Francesco Emma, will initially enroll adult patients. A November 5 research press release explicitly stated that the clinical program remains under regulatory review. At this stage, therefore, the experimental findings cannot be treated as evidence of efficacy in patients, nor do they establish that the drug can slow the deterioration of kidney function.
An important gap remains between improving protein recycling and actually changing the course of the disease. Adult patients may already have tissue damage that is difficult to reverse, and the findings from these kidney models are insufficient to infer benefits for eye or neurological symptoms. The study’s most concrete contribution at present is to connect the genetic defect, lipid imbalance and cellular transport into a mechanism that can be targeted, giving subsequent human trials a clear objective to test.